Skip to content

Sight Sciences, Inc. SGHT Return on equity

Return on equity at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
26.4%-3.0pp
Glaukos logo
GlaukosGKOS
-26.4%+11.1pp
AbbVie logo
AbbVieABBV
89%+32.7pp
Bausch + Lomb logo
Bausch + LombBLCO
-3.4%-0.9pp
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-14%-5.2pp
Boston Scientific logo
Boston ScientificBSX
14.8%+5.2pp

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K
Free cash flow-$7.1M+38.9%

Valuation

See full
Market cap$294.9M+35.0%
Enterprise value$250.83M+59.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Calculated from Sight Sciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s return on equity?
Sight Sciences, Inc. (SGHT) reported return on equity of -56.6% in Q1 2026.
How has Sight Sciences, Inc.'s return on equity changed year-over-year?
Sight Sciences, Inc.'s return on equity decreased by 7.1% year-over-year, from -52.9% to -56.6%.
What is the long-term trend for Sight Sciences, Inc.'s return on equity?
Over 3 years (2022 to 2025), Sight Sciences, Inc.'s return on equity has grown at a 4.9% compound annual growth rate (CAGR), from -44% to -50.7%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.